Skip to content

US · APGE · BIOTECHNOLOGY

Apogee Therapeutics, Inc. (APGE) intrinsic value and stock valuation

$135.07as of 2026-11-21 · Mkt cap 8.31B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Apogee Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values APGE with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from APGE’s statements →

Apogee Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Waltham, MA 02453 apogeetherapeutics.com

How the business is doing

Fiscal 2022–2025, USD

Revenue
$0.00
20222025
Net income
-$-255.84M
20222025
Free cash flow
-$-232.6M
20222025
Total equity
$903.9M
20222025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2022–2025, USD
2025202420232022
Revenue$0.00$0.00$0.00$0.00
Operating income-$-285.6M-$-216.87M-$-93M-$-30.73M
Net income-$-255.84M-$-182.15M-$-83.98M-$-39.78M
EPSd-$-4.22M-$-3.3M-$-1.66M-$-785.08K
Operating cash flow-$-227.45M-$-171.17M-$-74.76M-$-16.43M
Capital expenditure-$-5.15M-$-1.15M-$-170K$0.00
Free cash flow-$-232.6M-$-172.33M-$-74.93M-$-16.43M
Total assets$937.1M$754M$401.4M$152.1M
Total debt$8.85M$11.8M$2.03M$0.00
Net debt-$-122.7M-$-129.96M-$-116.28M-$-151.89M
Total equity$903.9M$716.8M$379.9M$142.1M
Cash and short-term investments$730.2M$520.7M$395.5M$151.9M
Income statement
2025202420232022
Revenue$0.00$0.00$0.00$0.00
Cost of revenue$1.42M$0.00$0.00$0.00
Gross profit-$-1.42M$0.00$0.00$0.00
Research and development expenses$214.7M$167.9M$68.4M$27.8M
Selling, general and administrative expenses$70.9M$49M$24.6M$2.94M
Other expenses$0.00$0.00$0.00$0.00
Operating expenses$284.2M$216.9M$93M$30.7M
Cost and expenses$285.6M$216.9M$93M$30.7M
Interest income$30M$34.7M$9.02M$90K
Interest expense$0.00$0.00$0.00$9.15M
Depreciation and amortization$1.42M$190K$9.02M$0.00
Ebitda-$-254.15M-$-181.94M-$-74.97M-$-39.78M
Operating income-$-285.6M-$-216.87M-$-93M-$-30.73M
Total other income/expenses, net$30M$34.7M$9.02M-$-9.06M
Income before tax-$-255.56M-$-182.13M-$-83.98M-$-39.78M
Income tax expense$280K$20K$0.00$0.00
Net income-$-255.84M-$-182.15M-$-83.98M-$-39.78M
Weighted average shares outstanding$60.7M$55.2M$50.7M$50.7M
Weighted average diluted shares outstanding$60.7M$55.2M$50.7M$50.7M
Balance sheet
2025202420232022
Cash and short-term investments$730.2M$520.7M$395.5M$151.9M
Net receivables$5.96M$4.7M$1.21M$0.00
Inventory$0.00$0.00$0.00$0.00
Total current assets$741.4M$529.7M$398.4M$152.1M
Property, plant and equipment, net$14.4M$13.3M$2.59M$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00
Long-term investments$0.00$210.4M$0.00$0.00
Total non-current assets$195.8M$224.2M$3M$0.00
Total assets$937.1M$754M$401.4M$152.1M
Accounts payable$1.22M$1.07M$2.14M$420K
Short-term debt$3.5M$3.23M$1.1M$0.00
Deferred revenue$0.00$0.00$0.00$0.00
Total current liabilities$27.9M$28.6M$20.6M$9.98M
Long-term debt$5.34M$8.6M$930K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00
Total non-current liabilities$5.34M$8.6M$930K$0.00
Capital lease obligations$3.5M$8.6M$930K$0.00
Total liabilities$33.3M$37.2M$21.5M$9.98M
Common stock$0.00$0.00$0.00$2.25M
Retained earnings-$-561.76M-$-305.92M-$-123.77M-$-39.78M
Accumulated other comprehensive income (loss)$1.08M$920K$330K$2.14M
Total equity$903.9M$716.8M$379.9M$142.1M
Total investments$598.6M$589.3M$277.1M$0.00
Total debt$8.85M$11.8M$2.03M$0.00
Net debt-$-122.7M-$-129.96M-$-116.28M-$-151.89M
Cash flow statement
2025202420232022
Net income-$-255.84M-$-182.15M-$-83.98M-$-39.78M
Depreciation and amortization$1.42M$190K$0.00$0.00
Stock-based compensation$46.3M$23.3M$6.1M$2.14M
Change in working capital-$-15.48M-$-2M$6.11M$9.81M
Accounts receivable$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00
Accounts payable$150K-$-1.07M$1.61M$420K
Net cash provided by operating activities-$-227.45M-$-171.17M-$-74.76M-$-16.43M
Investments in property, plant and equipment-$-5.15M-$-1.15M-$-170K$0.00
Acquisitions, net$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-179.57M-$-300.46M-$-273.91M$0.00
Common stock issued$396.5M$493.5M$315.4M$168.3M
Common stock repurchased$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00
Net cash used for financing activities$396.5M$495.1M$315.4M$168.3M
Net change in cash-$-10.53M$23.5M-$-33.28M$151.9M
Cash at end of period$131.6M$142.1M$118.6M$151.9M
Operating cash flow-$-227.45M-$-171.17M-$-74.76M-$-16.43M
Capital expenditure-$-5.15M-$-1.15M-$-170K$0.00
Free cash flow-$-232.6M-$-172.33M-$-74.93M-$-16.43M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Apogee Therapeutics, Inc.

        Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.

        CEO
        Michael Thomas Henderson
        Employees
        261
        Beta
        0.33

        Explore

        Frequently asked questions

        What is the intrinsic value of Apogee Therapeutics, Inc. (APGE)?

        InvestorsCraft does not currently publish an intrinsic value for APGE. How the IC value is calculated.

        Is APGE undervalued?

        InvestorsCraft does not publish an undervaluation signal for APGE at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.